These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38499379)

  • 1. Orexin antagonists for insomnia.
    Young J; Lee E; Lindblad AJ; Falk J
    Can Fam Physician; 2024 Mar; 70(3):183-184. PubMed ID: 38499379
    [No Abstract]   [Full Text] [Related]  

  • 2. Orexin Receptor Antagonists and Insomnia.
    Wu X; Xue T; Chen Z; Wang Z; Chen G
    Curr Psychiatry Rep; 2022 Oct; 24(10):509-521. PubMed ID: 35972717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging role of orexin antagonists in insomnia therapeutics: An update on SORAs and DORAs.
    Kumar A; Chanana P; Choudhary S
    Pharmacol Rep; 2016 Apr; 68(2):231-42. PubMed ID: 26922522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.
    Roecker AJ; Cox CD; Coleman PJ
    J Med Chem; 2016 Jan; 59(2):504-30. PubMed ID: 26317591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical usefulness of dual orexin receptor antagonism beyond insomnia: Neurological and psychiatric comorbidities.
    Carpi M; Palagini L; Fernandes M; Calvello C; Geoffroy PA; Miniati M; Pini S; Gemignani A; Mercuri NB; Liguori C
    Neuropharmacology; 2024 Mar; 245():109815. PubMed ID: 38114045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orexin, Sleep, Sympathetic Neural Activity, and Cardiovascular Function.
    Bigalke JA; Shan Z; Carter JR
    Hypertension; 2022 Dec; 79(12):2643-2655. PubMed ID: 36148653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual orexin receptor antagonists increase sleep and cataplexy in wild type mice.
    Mahoney CE; Mochizuki T; Scammell TE
    Sleep; 2020 Jun; 43(6):. PubMed ID: 31830270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current models of insomnia disorder: a theoretical review on the potential role of the orexinergic pathway with implications for insomnia treatment.
    Palagini L; Geoffroy PA; Balestrieri M; Miniati M; Biggio G; Liguori C; Menicucci D; Ferini-Strambi L; Nobili L; Riemann D; Gemignani A
    J Sleep Res; 2023 Aug; 32(4):e13825. PubMed ID: 36786121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Comprehensive Review of Daridorexant, a Dual-Orexin Receptor Antagonist as New Approach for the Treatment of Insomnia.
    Ziemichód W; Grabowska K; Kurowska A; Biała G
    Molecules; 2022 Sep; 27(18):. PubMed ID: 36144776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.
    Coleman PJ; Gotter AL; Herring WJ; Winrow CJ; Renger JJ
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():509-533. PubMed ID: 27860547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications.
    Herring WJ; Roth T; Krystal AD; Michelson D
    J Sleep Res; 2019 Apr; 28(2):e12782. PubMed ID: 30338596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preface.
    Steiner MA; Yanagisawa M; Clozel M
    Front Neurol Neurosci; 2021; 45():IX-X. PubMed ID: 34052818
    [No Abstract]   [Full Text] [Related]  

  • 13. The orexin story and orexin receptor antagonists for the treatment of insomnia.
    Muehlan C; Roch C; Vaillant C; Dingemanse J
    J Sleep Res; 2023 Dec; 32(6):e13902. PubMed ID: 37086045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of action of suvorexant.
    Stahl SM
    CNS Spectr; 2016 Jun; 21(3):215-8. PubMed ID: 27322687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Insomnia-Addiction Positive Feedback Loop: Role of the Orexin System.
    Fragale JE; James MH; Avila JA; Spaeth AM; Aurora RN; Langleben D; Aston-Jones G
    Front Neurol Neurosci; 2021; 45():117-127. PubMed ID: 34052815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel substituted octahydropyrrolo[3,4-c]pyrroles as dual orexin receptor antagonists for insomnia treatment.
    Wu S; Sun Y; Hu Y; Zhang H; Hou L; Liu X; Li Y; He H; Luo Z; Chen Y; Wang Y; Shi W; Shen L; Cao C; Liang W; Xu Q; Lv Q; Lan J; Li J; Chen S
    Bioorg Med Chem Lett; 2017 Mar; 27(6):1458-1462. PubMed ID: 28216404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Preclinical and clinical results of dual orexin receptor antagonist, suvorexant (BELSOMRA(®)), a novel therapeutic agent for insomnia].
    Tanaka Y; Aoki I; Ishine T; Renger JJ; Winrow CJ; Hisada S
    Nihon Yakurigaku Zasshi; 2016 Jul; 148(1):46-56. PubMed ID: 27430679
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders.
    Muehlan C; Vaillant C; Zenklusen I; Kraehenbuehl S; Dingemanse J
    Expert Opin Drug Metab Toxicol; 2020 Nov; 16(11):1063-1078. PubMed ID: 32901578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the role of orexins in the pathophysiology and treatment of depression: A comprehensive review.
    Shariq AS; Rosenblat JD; Alageel A; Mansur RB; Rong C; Ho RC; Ragguett RM; Pan Z; Brietzke E; McIntyre RS
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jun; 92():1-7. PubMed ID: 30576764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypocretin/Orexin Receptor Pharmacology and Sleep Phases.
    Sun Y; Tisdale RK; Kilduff TS
    Front Neurol Neurosci; 2021; 45():22-37. PubMed ID: 34052813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.